1,2; Elizabeth B. Gray, MPH2; Daniel S. Budnitz, MD3,4; Heather M. Strosnider, PhD1,5; Lyna Z. Schieber, MD, DPhil1,6; Joseph Courtney, PhD1,5; Macarena C.
García, DrPH1,7; John T. Brooks, MD8; William R. Mac Kenzie, MD1,7; Adi V. Gundlapalli, MD, PhD1,9 (View author affiliations)Hydroxychloroquine and chloroquine are approved to treat autoimmune diseases and to prevent and treat malaria.
Earlier this year, they were widely reported to be of potential benefit in the prevention and treatment of COVID-19; however, current data indicate that the potential benefits of these drugs do not outweigh their risks.New prescriptions by specialists who did not typically prescribe these medications (defined as specialties accounting for ≤2% of new.